The Dallas-based company is using its DeepView technology to aid the treatment of hard-to-heal and chronic wounds.
“Seeing the unknown” is the tagline for SpectralMD, a company that has developed an artificial intelligence-augmented imaging system to determine if a wound is healing.
Wound assessment is currently done primarily by eye, relying on experience, and oftentimes guesswork.
Amferia is developing an antimicrobial peptide hydrogel dressing to combat infections in acute wounds in humans and veterinary contexts. Supported by €1.2m of new venture capital financing, the company is planning pivotal clinical studies to support an FDA application later this year and CE mark submission in 2026-2027.
Cresilon CEO Joe Landolina says the newly FDA-cleared Traumagel for moderate and severe bleeding is easier to use than many currently available solutions like gauzes and sponges, and provides faster results.
Breathomics, UTI diagnosis and advanced wound healing innovations were among the center stage technologies at BioWales in London 2024. Hear from CEO John McKinley on Imspex Diagnostics' plans in embedded podcast.
Medtech Insight's News We're Watching highlights medtech industry developments that you may have missed over the last few weeks. Chinese researchers are working on a self-powered pacemaker, Carmat updated its artificial heart progress, a trial validates Smith & Nephew's Regeneten implant in shoulder surgery, experts back intravascular IVUS in peripheral interventions, and Spectral AI launches a new trial of its AI for burn evaluation.
Biopharmaceutical giant AstraZeneca has partnered with start-up “unicorn” Owkin to develop an AI-powered tool to prescreen for gBRCA mutations on the basis of morphological features in digitized pathology slides. Built on extensive, high-quality data sourced from the France-based PortrAIt consortium, the AI will help to prioritize patients for further testing, streamlining the diagnostic process, Owkin says.
An additional $50m brings the neurovascular intervention specialist’s total Series F funding to $82m. Route 92 says it will use the capital to build its sales and support teams and pursue regulatory authorizations around the globe for its FreeClimb portfolio while advancing its SUMMIT MAX clinical trial for the investigational Monopoint Reperfusion System.
TRiCares announced first implantation of the Topaz transfemoral tricuspid heart valve replacement system as part of the company’s EU pivotal study. If all goes to plan, the device will compete with Edwards’ Evoque system. The announcement follows the company’s $50m series D funding raise in July.
